Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 21.94
OPXA's Cash-to-Debt is ranked higher than
94% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. OPXA: 21.94 )
Ranked among companies with meaningful Cash-to-Debt only.
OPXA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 8.42 Max: No Debt
Current: 21.94
Equity-to-Asset 0.70
OPXA's Equity-to-Asset is ranked lower than
58% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OPXA: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
OPXA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1191  Med: 0.16 Max: 0.78
Current: 0.7
-1191
0.78
Interest Coverage No Debt
OPXA's Interest Coverage is ranked higher than
92% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPXA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPXA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -60.51
Beneish M-Score: -1.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -275.21
OPXA's Operating Margin % is ranked lower than
64% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. OPXA: -275.21 )
Ranked among companies with meaningful Operating Margin % only.
OPXA' s Operating Margin % Range Over the Past 10 Years
Min: -1184.59  Med: -707.1 Max: -275.11
Current: -275.21
-1184.59
-275.11
Net Margin % -274.79
OPXA's Net Margin % is ranked lower than
64% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. OPXA: -274.79 )
Ranked among companies with meaningful Net Margin % only.
OPXA' s Net Margin % Range Over the Past 10 Years
Min: -1314.6  Med: -826.78 Max: -274.7
Current: -274.79
-1314.6
-274.7
ROE % -132.24
OPXA's ROE % is ranked lower than
82% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. OPXA: -132.24 )
Ranked among companies with meaningful ROE % only.
OPXA' s ROE % Range Over the Past 10 Years
Min: -654.63  Med: -135.24 Max: -32.36
Current: -132.24
-654.63
-32.36
ROA % -85.71
OPXA's ROA % is ranked lower than
79% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. OPXA: -85.71 )
Ranked among companies with meaningful ROA % only.
OPXA' s ROA % Range Over the Past 10 Years
Min: -345.19  Med: -91.83 Max: -24.27
Current: -85.71
-345.19
-24.27
ROC (Joel Greenblatt) % -1330.23
OPXA's ROC (Joel Greenblatt) % is ranked lower than
63% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. OPXA: -1330.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPXA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1800  Med: -994.37 Max: -410.49
Current: -1330.23
-1800
-410.49
3-Year Revenue Growth Rate -15.10
OPXA's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. OPXA: -15.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OPXA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -15.1
Current: -15.1
3-Year EBITDA Growth Rate -47.20
OPXA's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OPXA: -47.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OPXA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.7 Max: 43.2
Current: -47.2
0
43.2
3-Year EPS without NRI Growth Rate -49.60
OPXA's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OPXA: -49.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPXA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -42.7 Max: 51.8
Current: -49.6
0
51.8
GuruFocus has detected 3 Warning Signs with Opexa Therapeutics Inc $OPXA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPXA's 10-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OPXA Guru Trades in Q1 2016

Jim Simons 148,189 sh (+9.54%)
» More
Q2 2016

OPXA Guru Trades in Q2 2016

Jim Simons 169,089 sh (+14.10%)
» More
Q3 2016

OPXA Guru Trades in Q3 2016

Jim Simons 198,689 sh (+17.51%)
» More
Q4 2016

OPXA Guru Trades in Q4 2016

Jim Simons 11,305 sh (-94.31%)
» More
» Details

Insider Trades

Latest Guru Trades with OPXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:AEMAF, OTCPK:GRSO, OTCPK:OPLI, OTCPK:MDFZF, OTCPK:LIBFF, OTCPK:SGBI, OTCPK:CTBO, OTCPK:BIEI, OTCPK:CBBT, OTCPK:CLYXF, OTCPK:GNBT, OTCPK:CTTC, OTCPK:SVON, OTCPK:AMAR, OTCPK:BTHE, OTCPK:VXLLF, OTCPK:GOVX, OTCPK:ADYNF, OTCPK:ARNI, OTCPK:ISCO » details
Traded in other countries:P6NP.Germany,
Headquarter Location:USA
Opexa Therapeutics Inc is a biopharmaceutical company engaged in developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases such as neuromyelitis optica.

Opexa Therapeutics, Inc., formerly known as PharmaFrontiers Corp., was incorporated in Texas in March 1991. The Company's therapy is based on its proprietary T-cell technology. Opexa initiated a Phase IIb clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Tcelna has received Fast Track designation from the FDA in secondary progressive multiple sclerosis. Tcelna's combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of multiple sclerosis. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies in the United States and abroad.

Top Ranked Articles about Opexa Therapeutics Inc

Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update

Conference Call Scheduled Today at 4:30 PM ET

THE WOODLANDS, TX--(Marketwired - May 12, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including Tcelna® for multiple sclerosis (MS) and OPX-212 for neuromyelitis optica (NMO), today reported financial results for the quarter ended March 31, 2016, and provided an update on the Company's recent corporate developments. "We are pleased to be coming off a productive quarter and progressing further towards the completion of our Phase 2b Abili-T trial in secondary progressive MS," stated Neil K. Warma, President and Chief Executive Officer of Opexa. "Approximately 98% of all patient visits in the Abili-T trial have been completed, and we are excited to be approaching the release of our top-line data expected in early fourth quarter of this year. The trial is being conducted in over 180 patients and is coupled with a comprehensive immune monitoring, biomarker study. We believe this is the first clinical trial that is delivering a personalized T-cell immunotherapy to patients with secondary progressive MS and we are hopeful that we may be the first to commercialize a safe and effective therapy for these individuals. There are currently no treatments for patients with secondary progressive MS so the unmet medical need is significant and the market for this indication could be significant. As Tcelna has been partnered, through an option and license agreement, with Merck Serono, Opexa hopes to be able to leverage our combined expertise to move into a Phase III clinical trial should the Phase 2b data be positive." "We were also pleased that Opexa was invited to present at the Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, in Vatican City, and to participate in the important discussions surrounding the potential of immunotherapies to transform the treatment of diseases with serious unmet medical need, such as secondary progressive MS and neuromyelitis optica. We are continuing to advance OPX-212 through preclinical development for NMO and are pleased with the progress demonstrated on this program during this quarter," added Mr. Warma. Business Highlights Clinical and Preclinical Efforts

The Phase 2b clinical trial of Tcelna® (imilecleucel-T) in secondary progressive multiple sclerosis (SPMS) (Abili-T trial) continued to advance towards completion. Top line data is expected in early fourth quarter of 2016. The final dose was administered to the last patient in the last week of February 2016 and approximately 98% of all patient visits have now been completed. The Abili-T clinical trial is a randomized, double-blind, placebo-controlled study being conducted at approximately 35 leading clinical sites in the U.S. and Canada. Opexa has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Tcelna in SPMS.
In February 2016, a regularly scheduled meeting of the independent Data Safety Monitoring Board (DSMB) took place. The DSMB recommendation was to continue the Abili-T study as per protocol. The DSMB also stated that because dosing has been completed and no concerns over safety had been noted, no further DSMB meetings would be required for the Abili-T study.





Corporate Activities

In April 2016, Neil K. Warma, Opexa's President and Chief Executive Officer, was invited to present at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, in Vatican City. Mr. Warma was among the world's leading cell therapy scientists, physicians, patients, ethicists and leaders of faith, government and philanthropists discussing the latest cellular therapy breakthroughs and the hope they provide for the future treatment of disease. Mr. Warma's presentation was entitled, "Can T-cells be Used to Treat Neuromyelitis Optica (NMO) and Other Autoimmune Disorders?"





Financial Results for the Quarter Ended March 31, 2016

Cash position: Cash and cash equivalents were $9,955,449 as of March 31, 2016, compared to $12,583,764 as of December 31, 2015.



R & D Expense: Research and development expenses were $1,829,062 for the quarter ended March 31, 2016, compared to $2,636,999 for the quarter ended March 31, 2015. The decrease in expenses is primarily due to a decrease in the costs in connection with the ongoing clinical trial of Tcelna in SPMS, a decrease in the procurement and use of supplies for product manufacturing and development, a decrease in employee and stock-based compensation expense as well as a reduction in the facility cost.



G & A Expense: General and administrative expenses were $987,248 for the quarter ended March 31, 2016, compared to $1,006,130 for the quarter ended March 31, 2015. The decrease in expenses is primarily due to the reduction in employee stock-based compensation expense and a decline in consulting services. This is offset by an increase in employee compensation including severance payments and severance accruals due to the March 2016 restructuring initiative.



Net loss: Net loss reported for the quarter ended March 31, 2016 was $2,160,394, or $.31 per share (basic and diluted), compared with a net loss of $3,350,880, or $.95 per share (basic and diluted), for the quarter ended March 31, 2015. The decreased net loss is primarily related to the decrease in research and development expenses, specifically site payments relating to the ongoing Abili-T clinical trial and related lab supplies. The decreased net loss is also due to the increase in revenue of $348,838 recognized in connection with the additional $3.0 million in funding from Merck Serono for Phase III planning which was received in March 2015. General and administrative expenses, specifically a reduction in the Black Sholes and consulting expenses, also reduced our net loss for the three months ended March 31, 2016.





Financial Guidance

Based on the current activities of the Company and projected burn, Opexa believes it has sufficient liquidity to support its current clinical activities for the Abili-T trial of Tcelna in SPMS, to continue planned preclinical development activities for OPX-212 in NMO, and for general operations to sustain the Company and support such activities through the first quarter of 2017. Opexa expects top-line data for the Abili-T trial to be available early in the fourth quarter of 2016, and thus believes it has sufficient resources to complete such trial.





For additional information please see Opexa's Quarterly Report on Form 10-Q filed today with the SEC. Conference Call and Webcast Details To listen to the 4:30 P.M. ET conference call, dial 201-689-8040 or toll free 877-407-8133. The conference ID number is 13636799. A live webcast of the call can also be accessed here or via the webcast link on the Investor Relations page of Opexa's website (www.opexatherapeutics.com). An archive of the webcast will be available on the Company's website until August 12, 2016. There will be a brief Question & Answer session following management commentary.  About Opexa Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase 2b clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com or follow company news on Twitter via @OpexaCEO. Cautionary Statement Relating to Forward-Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995 Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as Tcelna® and OPX-212 as well as the sufficiency of our resources, constitute forward-looking statements. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation our ability to raise additional capital to continue our development programs, our ability to successfully develop potential products such as Tcelna and OPX-212, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna and OPX-212), as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2015 and our Quarterly Reports on Form 10-Q. All forward-looking statements contained in this release speak only as of the date on which they were first made by us, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after such date.


 

OPEXA THERAPEUTICS, INC.


CONSOLIDATED STATEMENTS OF OPERATIONS


(Unaudited)


 


 
 
Three Months

Ended March 31,
 


 
 
2016
 
 
2015
 


Revenue:
 
 
 
 
 
 


 
Option revenue
 
$
726,291
 
 
$
377,453
 


Expenses:
 
 
 
 
 
 
 
 


Research and development
 
 
1,829,062
 
 
 
2,636,999
 


General and administrative
 
 
987,248
 
 
 
1,006,130
 


Depreciation and amortization
 
 
72,589
 
 
 
96,982
 


 
Operating loss
 
 
(2,162,608
)
 
 
(3,362,658
)


Interest income, net
 
 
108
 
 
 
731
 


Other income, net
 
 
2,106
 
 
 
11,047
 


 
Net loss
 
$
(2,160,394
)
 
$
(3,350,880
)


 
 
 
 
 
 
 
 
 


Basic and diluted loss per share  
$
(.31
)
 
$
(.95
)


 
 
 
 
 
 
 
 
 


Weighted average shares outstanding - Basic and diluted
 
 
6,982,909
 
 
 
3,529,344
 






 
 
 
 


 
 
 
 


Selected Balance Sheet Data:
 
 
 


 
March 31,

2016
 
December 31,

2015


 
 
 


Cash and cash equivalents
$
9,955,449
 
$
12,583,764


Other current assets
 
932,409
 
 
995,067


Property and equipment, net
 
765,763
 
 
837,867


Total assets
 
11,653,621
 
 
14,416,698


Total current liabilities
 
4,044,900
 
 
4,801,436


Total stockholders' equity
 
7,608,721
 
 
9,615,262


Total liabilities and stockholders' equity
$
11,653,621
 
$
14,416,698


 
 
 
 
 
 





Company Contact:



Opexa Therapeutics, Inc.

Camilla Zuckero

281.775.0609

[email protected]





Read more...
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results

THE WOODLANDS, TX--(Marketwired - May 10, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the quarter ended March 31, 2016 after the close of trading on Thursday, May 12th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. ET on Thursday, May 12th. Conference Call and Webcast Details
To listen to the 4:30 P.M. conference call, dial 201-689-8040 or toll free 877-407-8133. The conference ID number is 13636799. A live webcast of the call can also be accessed here or via the webcast link on the Investor Relations page of Opexa's website (www.opexatherapeutics.com). An archive of the webcast will be available on the Company's website until August 12, 2016. There will be a brief Question & Answer session following management commentary.  About Opexa Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the same patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com or follow company news on Twitter via @OpexaCEO.


Company Contact:

Opexa Therapeutics, Inc.

Camilla Zuckero

281.775.0609

[email protected]





Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.79
OPXA's PB Ratio is ranked higher than
87% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. OPXA: 1.79 )
Ranked among companies with meaningful PB Ratio only.
OPXA' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.58 Max: 11.14
Current: 1.79
0.96
11.14
PS Ratio 1.64
OPXA's PS Ratio is ranked higher than
88% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. OPXA: 1.64 )
Ranked among companies with meaningful PS Ratio only.
OPXA' s PS Ratio Range Over the Past 10 Years
Min: 1.33  Med: 11.92 Max: 77.02
Current: 1.64
1.33
77.02
EV-to-EBIT -0.24
OPXA's EV-to-EBIT is ranked higher than
98% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. OPXA: -0.24 )
Ranked among companies with meaningful EV-to-EBIT only.
OPXA' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.8  Med: -0.6 Max: 0.2
Current: -0.24
-2.8
0.2
EV-to-EBITDA -0.25
OPXA's EV-to-EBITDA is ranked higher than
98% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. OPXA: -0.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPXA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.9  Med: -0.6 Max: 0.2
Current: -0.25
-2.9
0.2
Current Ratio 3.29
OPXA's Current Ratio is ranked lower than
73% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. OPXA: 3.29 )
Ranked among companies with meaningful Current Ratio only.
OPXA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.77 Max: 10.03
Current: 3.29
0.01
10.03
Quick Ratio 3.29
OPXA's Quick Ratio is ranked lower than
69% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OPXA: 3.29 )
Ranked among companies with meaningful Quick Ratio only.
OPXA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.77 Max: 10.03
Current: 3.29
0.01
10.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -30.40
OPXA's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. OPXA: -30.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPXA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -393.2  Med: -70.1 Max: 0
Current: -30.4
-393.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.13
OPXA's Price-to-Net-Cash is ranked higher than
88% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. OPXA: 2.13 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OPXA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.31  Med: 4.21 Max: 40.46
Current: 2.13
2.31
40.46
Price-to-Net-Current-Asset-Value 1.84
OPXA's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. OPXA: 1.84 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OPXA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.17  Med: 4.6 Max: 21.63
Current: 1.84
2.17
21.63
Price-to-Tangible-Book 1.79
OPXA's Price-to-Tangible-Book is ranked higher than
90% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. OPXA: 1.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OPXA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.56  Med: 2.74 Max: 7.74
Current: 1.79
1.56
7.74
Price-to-Median-PS-Value 0.13
OPXA's Price-to-Median-PS-Value is ranked higher than
95% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OPXA: 0.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPXA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 0.83 Max: 1.22
Current: 0.13
0.18
1.22
Earnings Yield (Greenblatt) % -416.67
OPXA's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. OPXA: -416.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPXA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 507.8  Med: 1275.3 Max: 5805
Current: -416.67
507.8
5805

More Statistics

Revenue (TTM) (Mil) $2.90
EPS (TTM) $ -1.13
Beta1.94
Short Percentage of Float8.00%
52-Week Range $0.50 - 4.93
Shares Outstanding (Mil)7.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.89 -1.73 -0.09
EPS without NRI ($) -1.89 -1.73 -0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OPXA

Headlines

Articles On GuruFocus.com
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update May 12 2016 
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 May 10 2016 
Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Apr 27 2016 
Opexa Therapeutics Reports 2015 Year End Financial Results and Provides Corporate Update Mar 15 2016 
Opexa Launches Restructuring Initiative to Focus Use of Resources Ahead of Key Phase 2 Data Expected Mar 02 2016 
Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference Jan 28 2016 
Taglich Brothers Initiates Coverage on Opexa Therapeutics, Inc. Sep 02 2015 
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017 Mar 30 2017
Opexa Therapeutics Reports 2016 Year End Financial Results and Provides Corporate Update Mar 28 2017
Opexa Facility Becomes Foundation for Contract Manufacturing and Development Organization for... Feb 01 2017
These 5 Stocks Under $10 Could Explode Higher Soon Jan 12 2017
ETFs with exposure to Opexa Therapeutics, Inc. : December 23, 2016 Dec 23 2016
ETFs with exposure to Opexa Therapeutics, Inc. : November 18, 2016 Nov 18 2016
Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 Nov 15 2016
Biotech Movers on Thursday: Cempra Inc (CEMP) And Opexa Therapeutics Inc (OPXA) Nov 03 2016
Opexa Announces Reduction in Workforce in Light of Top-Line Results from Phase 2b Abili-T Trial of... Nov 02 2016
6 Companies That Destroyed Shareholders Last Week Oct 29 2016
GNC Deal Could Be In Jeopardy, Genocea Taming Herpes, Opexa Not Taming MS, Plus The Latest on... Oct 28 2016
Is This the Beginning of the End of Opexa? Oct 28 2016
Opexa Therapeutics Announces Phase 2b Abili-T Trial of Tcelna(R) (imilecleucel-T) in Secondary... Oct 28 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : October 17, 2016 Oct 17 2016
Opexa Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference Sep 07 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : August 12, 2016 Aug 12 2016
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 11 2016
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter... Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)